 "What do genetic studies tell us about the heritable basis of common epilepsy?
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Introduction.
It has been well recognised that people with epilepsy are more likely to have family members that also have seizures. This familial component of epilepsy is provides evidences that heritable genetic factors play a role in the susceptibility of disease. Currently, the field of epilepsy genetics is making giant leaps in detection of monogenic forms of epilepsy, where a single mutation in the coding region of an epilepsy gene is believed to cause disease and may predict the occurrence of disease at a level close to 100%. Such strong correlations are not detected for the most common forms of epilepsy, including generalised and nonacquired focal epilepsy. For these epilepsies it is believed that multiple factors, both genetic and non-genetic, can influence the susceptibility for disease. This review summarised the results of some relevant studies that point to a polygenic background of common epilepsy.
Common epilepsy is defined as a general term for the most common epilepsy syndromes, affecting more than ~1 in 200 people, characterized by recurrent generalised, or partial seizures. This definition encompasses the most common epilepsy syndromes, Genetic Generalised Epilepsy (GGE, including Juvenile Myoclonic Epilepsy (JME) and Idiopathic Absence Epilepsy (IAE)) and Focal Epilepsy (FE, including Temporal Lobe Epilepsy (TLE) and Idiopathic Focal Epilepsy (IFE)).
Establishing heritability: estimates of genetic architecture from genetic epidemiology.
Firm evidence for a genetic cause of epilepsy susceptibility is provided by twin studies that compare disease concordance between monogenic and dizygotic twins to estimate the heritability of the trait of interest. By doing so, the effect of the environment can be cancelled out, assuming that both types of twins share the same environment, leaving the difference in shared genetic variation to explain any difference in disease concordance (monozygotic twins share 100% of all genetic variation, whereas dizygotic twins share ~50% of genetic variation inherited from their parents). Giving this difference in shared inherited genetic variation within a (presumed) constant environment, any difference in disease occurrence can be attributed to genetics. Fortunately for epilepsy, such twin studies have been performed for a relatively large number of twins in multiple independent studies, and their estimate of heritability is believed to be reliable. The first twin study of epilepsy was performed by Lennox in 1940 and 1950 and still holds relevance today [1, 2] . It showed that monozygotic twins share their epilepsy phenotype more often than expected by chance, providing evidence for a genetic basis. More recent studies have been performed using reliable epidemiological principles; however, these only confirmed earlier estimates and show highly increased concordance rates in monozygotic twins compared to dizygotic twins (0.77 versus 0.35 for GGE, 0.85 versus 0.25 for GGE with FS, and 0.40 versus 0.03 for FE) [3] [4] [5] .
Early gene discovery in monogenic epilepsy; the 'channelopathy' era.
Despite this early recognition of a genetic basis for epilepsy, and the observation of several distinct epilepsy syndromes 'running in' families, gene identification proved difficult in the early years. In 1995 the first epilepsy gene mutation, a missense mutation in CHRNA4 was discovered in a large Australian family with Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE) through linkage analysis and subsequent sequence analysis of the gene [6] . This finding was quickly followed by the 'channelopathy era' in which a series of gene discoveries was made in monogenic familial epilepsies that included the discovery of SCN1A in families with Generalised Epilepsy with Febrile Seizures plus (GEFS+), and KCNQ2 and KCNQ3 in families with Benign Familial Neonatal Convulsions (BFNC) [7] [8] [9] [10] Linkage analysis remains an important tool for the analysis of autosomal dominant or recessive forms of common epilepsy, such as is observed in rare families with JME [11] [12] [13] . Several genes have been reported in which mutations have been found to co-segregate with common epilepsy in some rare families, including EFHC1 and GABRA2. However, these observation seem limited to just a handful of families and are generally not extended to a significant proportion of common epilepsy families. Therefore, it seems that rare Mendelian variants with relative large effects, that can explain segregation of disease in extended families, only explain a small proportion of the heritability of common epilepsy.
Family studies in common epilepsy, the 'linkage' era.
The early efforts to map the first common genetic risk factor for epilepsy concentrated on genome-wide linkage analysis of larger collections of small-to medium-sized families with Genetic Generalised Epilepsy (GGE). GGE was chosen for reasons including of a relatively large number of available families with a sufficient number of affected individuals, clear clinical presentation, unambiguous phenotyping, and a disease segregation that resembles Mendelian transmission with similar clinical expression in close relatives. These prerequisites make Juvenile Myoclonic Epilepsy (JME) and Idiopathic Absence Epilepsy (IAE) particularly suitable for successful linkage analysis, and a large number of studies with growing number of families and affected individuals have been performed. Together, these studies have reported linkage to many different chromosomal regions, but unfortunately there is a lack of consistency. Many reported loci were not confirmed by independent studies and none of the reported linked regions have resulted in unambiguous mapping of a major susceptibility gene for GGE. The largest linkage analysis of GGE to date included 379 multiplex families with 982 affected family members, which was also analysed in subgroups of absence epilepsy (235 families) and JME families (118 families) [14] . Despite the sizable number of affected individuals and families, only two genome-wide significant loci were detected (at chromosome 5q34 for IAE, and chromosome 13q31.3 for a recessive model in GGE). However, six loci showed suggestive evidence for linkage (chromosomal segments 1p36.22, 3p14.2, 5q34, 13q12.12, 13q31.3, and 19q13.42), which was taken as evidence for an oligogenic inheritance of GGE, since only one suggestive hit is expected by chance. Finally, the locus at chromosome 5q34 was considered the most interesting, as it maps close to the gene cluster encoding the GABAAβ2-, α6-, α1-, and γ2 subunits (GABRB2, GABRA6, GABRA1, GABRG2). This peak therefore connects with the previous identification of GABRA1 and GABRG2 mutations in GGE and JME [15, 16] .
Extended families suitable for linkage are rare for common focal epilepsies. However, some linkage studies have been performed on familial Temporal Lobe Epilepsy, and Idiopathic Focal Epilepsy, which reported linkage for several different loci, however, similar to the observations in GGE, these findings are not consistently confirmed [17] [18] [19] [20] [21] .
Together, the lack of confirmation between similar linkage studies, and the non-overlapping results of recent genome-wide association, suggests that most linkage studies of common non-Mendelian epilepsy suffer from lack of power. This is likely caused by a high degree of genetic heterogeneity. Nevertheless, it remains remarkable that multi-generation GGE families with similar clinical expression in close relatives exist, which argues against a complex genetic inheritance. These two observations, the evidence for a genetic heterogeneity and non-Mendelian inheritance versus clear familial clustering, argue for polygenic inheritance with a limited number of genes acting in concert to increase the susceptibility for epilepsy.
Candidate gene studies true or false?
Similarly, a large number of candidate gene association studies were performed for common epilepsy, which marked the pre-Genome-Wide Association Study (GWAS) era in common disease gene mapping. These studies, although performed appropriately and with scientific rigor, again showed a high degree of conflicting results, and no candidate gene was shown to be unambiguously associated with common epilepsy [22] [23] [24] [25] . This is, however, not unexpected considering the arguments made in a seminal paper by Neil Risch that showed that association and linkage studies of common diseases needed much larger sample sizes to have sufficient power for reliable results [26] . Given these arguments, it is likely that many of the reported linkages and associations in most common diseases including epilepsy are false-positives [26, 27] . The sample sizes needed for reliable gene identification have now been accomplished for GWAS of epilepsy, which has the additional advantage of being 'hypothesis free'.
Large Case-control studies: the 'GWAS' era GWAS studies are firmly based on the principles of the 'common disease common variant' hypothesis, which argues that many common variants (~30-40% frequency in the general population) conferring low risk for disease (relative risks ~1.1) together determine the genetic susceptibility for disease [27] . This theory fits the epidemiological characteristics of many common diseases such as diabetes, auto-immune diseases, and common neurological and psychiatric diseases, where many sporadic patients, some sib-pairs, and relatively few extended families are observed. Whether this theory also holds for common epilepsy, in particular for GGE, where frequent familial aggregation may argue for a polygenic inheritance with a high genetic heterogeneity that is less suited for the GWAS approach remains the question. Indeed, the results of GWAS of epilepsy have been modest so far, yet it is likely that with growing sample sizes many common epilepsy susceptibility loci will be detected.
The first large GWAS of epilepsy was performed in 3,445 people with partial epilepsy and 6,935 controls; both groups were of European ancestry [28] . The study included a broad spectrum of partial epilepsy syndromes that included people with non-idiopathic focal epilepsy, such as Malformation of Cortical Development, brain tumour, trauma, stroke, and perinatal insults. However, the two largest categories consisted of 919 people with mesial Temporal Lobe Epilepsy (mTLE) with Hippocampal Sclerosis (HS), and focal epilepsies with unknown cause. This study, pooling patients with different types of focal epilepsies, therefore tested whether common shared genetic variants predispose to partial epilepsy. However, the study did not detect any significant associated locus, despite having 80% power to detect common variants with an odds ratio above 1.25-1.3, and close to 100% power to detect common variants with an odds ratio above 1.35-1.4. The highest associated Single Nucleotide Variants (SNPs) were located close to probable candidate genes. Furthermore, when genes with SNPs with low p-values were analysed, significant gene ontology enrichment was observed for ion-channel and receptor genes.
Apart from gene discovery, GWAS data can be used to infer heritability, genetic architecture, and the shared genetic background between disease entities, using advanced statistical methods. Speed et al applied an extension of SNP-based heritability analysis to estimate the contribution of common risk variants to the disease variance, and assessed genetic overlap between focal and non-focal epilepsy [29] . These analyses were performed with cohorts of 1,258 and 5,129 control individuals. The majority of cases consisted of people with FE. As expected, no SNP was found to be significantly associated with epilepsy in this relatively small sample when applying the accepted genome-wide significance level of 5x10 -08 . However, the cohort was sufficiently sized to estimate the fraction of disease variance explained by autosomal SNPs, obtained with the quantification of allelic correlations between subjects. These estimations showed that common SNPs explain around 26% of phenotypic variation of all epilepsy, and 27% of FE only. Further estimates predicted that epilepsy is a highly polygenic trait with at least 400 susceptibility loci, but potentially could have several thousand loci that individually confer very modest risks. This result, which was made in mainly focal epilepsy, has great consequences for the design of gene discovery projects in FE, as it suggests that GWAS using very large case-control cohorts, including several tens of thousands of people with epilepsy, would be required to have sufficient power to detect such low risk variants. Such a genetic architecture is nevertheless not unlikely in common disease, and several examples of such high genetic heterogeneity of hundreds of low risk factors currently exists, such as in GWAS studies of more than a hundred thousand cases with cardiac disease, or related phenotypes, and in studies of nonclinical traits such as height, body weight, and blood pressure [30] [31] [32] .
The utility of subphenotypes to increase genetic homogeneity
Sub-phenotypes that characterise individual epilepsy syndromes have been used extensively in epilepsy gene mapping. This approach is motivated by the assumption that a certain subphenotype may be a marker for a single underlying genetic risk factor and will therefore reduce genetic heterogeneity leading to increased power for detection. For some broad subphenotypes, this approach has been somewhat successful, such as the focus on JME families [11, 12] . However, for others, such as the EEG trait PhotoParoxysimal Response (PPR), it did not result in more consistent results [33, 34] . In GWAS, a focus on febrile seizures has however been successful and several susceptibility genes or loci have been mapped by two large studies. Febrile seizures are a relatively common occurrence in children between 6 month and five years of age, being reported in 2-5% of children. It is defined as a seizure associated with fever or high body temperature, and in most cases it is the only clinical symptom. However, there is an increased risk of the development of epilepsy later in life, and a number of epilepsy syndromes have a firm association with a history of febrile seizure, such as Generalised Epilepsy Febrile Seizures plus and the more severe Dravet syndrome and mTLE with HS [35] . Furthermore, twin studies have shown a strong genetic component for febrile seizures, making it a prime sub-phenotype for gene mapping studies [36, 37] .
These observations motivated Kasperavičiūte and colleagues to search for common variants that could confer risk for mTLE and HS with or without FS [38] . They performed a discovery GWAS in 1,018 people with mTLE and HS and 7,552 control subjects and subsequent validation in a second cohort of 959 people with mTLE and HS and 3,591 controls. A specific FS analysis was performed in the subset of cases with (757) and without (803) FS. Suggestive evidence was detected in the discovery stage and extended to genome-wide significance in a meta-analysis of the discovery and validation cohort for SNPs within SCN1A. This association was confined to the subset of people with mTLE and HS and a history of FS. This observation is remarkable, as it extends the phenotypic and genetic spectrum of SCN1A-related epilepsy from rare mutations that cause monogenic epilepsies to common variants underlying common epilepsy.
Febrile seizures and common epilepsy
The association of SCN1A with febrile seizures as a phenotype that is independent of a specific epilepsy syndrome was further corroborated in another GWAS study in children that developed FS after measles, mumps and rubella vaccination (1,334 cases), children with FS unrelated to vaccination (2,100 cases), and controls without a history of FS (5,742 subjects), using a discovery and replication phase [39] . Remarkably, of the four genes associated with overall FS, two were known epilepsy genes, namely SCN1A and SCN2A. Only a small minority of cases (3.7-4.6%) were diagnosed with epilepsy after a median of 15 years follow-up, but this is a clear increase compared to the general population prevalence (0.5%). This observation confirms the link between FS and epilepsy, yet suggests that SCN1A and SCN2A are also associated with FS without epilepsy. It remains to be elucidated whether variants underlying susceptibility for common epilepsy are identical to those underlying FS. This seems likely under the hypothesis that FS is an independent endophenotype of epilepsy with a less complex genetic background.
Rare chromosomal Copy Number Variants in common epilepsy
GWASs are performed by automated SNP genotyping using SNP arrays, which determine SNP-alleles by fluorescent hybridization of allele-and locus-specific probes. As a consequence, the fluorescent genotyping allows for the quantitative assessment of SNPalleles and can thus detect chromosomal deletions and duplications, i.e. Copy Number Variations (CNVs). The advantage of SNP arrays over traditional karyotyping is their resolution, and these arrays can detect very small CNVs down to a few kilobases in size. In the run-up to the first large GWAS in GGE, CNVs were detected as rare risk factors for GGE. This was a major step forward in the elucidation of the genetic architecture of common epilepsy. The first publication by Helbig and colleagues reported 12 out of 1,223 cases with GGE carrying a 15q13.3 microdeletion that was not observed in 3,669 controls [40] . Remarkably, this deletion was already associated with a range of neurodevelopmental disorders, including mental retardation, schizophrenia, and autism. The association of rare recurrent CNVs with GGE was further extended to several other CNVs (microdeletions of 1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p13.11 and 22q11.2), which were also associated with other neurodevelopmental diseases [41] . It has become clear that even rarer CNVs can confer susceptibility to GGE, as evidenced by the observed increased burden of rare microdeletions [42, 43] . The frequency of CNV seems higher in people with epilepsy and mental or psychiatric disorders [44, 45] . Finally, CNVs are also found across different epilepsy syndromes including idiopathic focal epilepsy [46 -48] . These observations have demonstrated that rare genetic variants, with intermediate risk are important, and may constitute a sizable fraction of the heritability of common epilepsy.
GWAS of common epilepsy, GGE
The first large-scale GWAS of common generalised epilepsy was performed as a two stage study including 1,527 people with GGE and 2,461 controls in the discovery GWAS followed by validation in 604 parent-offspring trios of children with GGE [49] . Genome-wide significance was detected for two loci at 2p16.1 and 17q21.32. The subgroup analysis revealed significance for a locus at 2q22.3 for absence epilepsy and 1q43 for JME. Remarkably, suggestive association was detected for SCN1A, further strengthening its role for common epilepsy. However, the relatively small sample size for a common disease GWAS, the multiple tests invoked by the subgroup analysis, and the two stage design required the confirmation of these associations by independent studies. Such a study came about by the conception of an international collaboration aimed at bringing together all available epilepsy cohorts with genome-wide genotyping for a large met-GWAS analysis, the ILAE consortium on complex epilepsies ( http://www.ilae.org/Commission/class/consortium.cfm ). The formation of this consortium was an important step forward, as it became clear that much larger sample sizes were needed to reliably detect the common risk variants for epilepsy. The results of the previous studies suggested that the genetic background of common epilepsy was characterised by high genetic heterogeneity, and likely many common variants with very low effect sizes, requiring very large sample sizes of up to ten thousand cases.
The meta-GWAS of the consortium was performed by combining genome-wide association data of 12 independent cohorts, totalling 8,696 cases and 26,157 controls. The most significant association was found for SNPs in the SCN1A gene, further confirming its importance as the gene associated with common epilepsy [50] . Of note, this finding did not constitute a formal replication of previous SCN1A associations, as this study had considerable sample overlap with the previous studies. One novel locus was detected at 4p15.1 implicating PCDH7. Finally, the subgroup analysis for GGE further strengthens the association found for 2p16.1 that contains the genes VRK2 and FANCL.
Overall, and compared to the GWAS of other neurological diseases, the results of the studies described above appear modest. This most likely reflects the complex genetic architecture of epilepsy, a high degree of heterogeneity that is opposed by the apparent suggestion that the detected loci act pleiotropically and confer a risk for the wide clinical spectrum of common epilepsy. The ILAE consortium on complex epilepsies GWAS is still modest in size as compared to those of other complex diseases such as schizophrenia or migraine, which now have cohorts of more than fifty thousand cases and have identified between 108 and 38 independent risk loci respectively [51] . Given the promising results of epilepsy GWAS to date (Table 1) , and heritability analyses performed on these data, it is expected that a similar number of epilepsy susceptibility loci can be detected given sufficient sample sizes.
The sequencing revolution: the 'Next Generation Sequencing' era
The introduction of Next Generation Sequencing has revolutionised genetic research as it has made cheap and massive sequencing available. Whole Exome Sequencing (WES) now provides researchers with the coding sequence of all human genes, and has progressed gene identification in quantum leaps. Since its introduction, WES has been used to detect hundreds of new disease genes. In epilepsy, WES had the largest impact on gene discovery of sporadic severe Epileptic Encephalopathy, for which de novo mutations in many new genes are still being discovered [52] . WES and Whole Genome Sequencing (WGS) are very effective techniques that directly detect putative disease mutations. This is in sharp contrast to the methods used in the past that were based on the principles of linkage disequilibrium (LD mapping) using neutral variants as markers of the undetected disease mutation. Linkage, association and GWAS analysis rely on LD mapping, and are subject to confounders and assumptions about genetic architecture. However, LD mapping methods are still valuable today, since they are optimal for the detection of a certain class of disease variants. Linkage and WES can detect monogenic rare variants with large effects that are either inherited (linkage and WES) or de novo (WES). In contrast, GWAS is firmly based on the common disease common variant hypothesis that assumes that many common risk variants underlie the majority of the disease variance in common disease [27] . WES is less cost-effective for common disease variant detection, as this would require a very large number of cases to be sequenced. Furthermore, WES detects all variants present in all genes and the biggest challenge is therefore weeding out the neutral variants, to detect the needle in the haystack mutation. Therefore, WES is the best method for rare to medium-rare variant detection with relative large effect sizes that can be predicted to have a putative deleterious effect on the function of the encoded protein. Similarly, the challenge of WGS is the interpretation of detected variants and the prediction of their pathogenicity.
Early large-scale gene sequencing studies of common epilepsy suggested that rare functional variants could indeed underlie disease. The first sequencing study performed parallel sequencing of 237 ion channel genes and tested for the enrichment of coding variants in sporadic Idiopathic Epilepsy cases compared to controls [53] . The analysis showed distinct, but complex profiles of rare putative variations among the analysed genes. The authors did not claim any significant overrepresentation of putative functional variation in any particular gene, but their results suggested that rare variation in known and novel epilepsy genes can underlie common epilepsy. A recent follow-up showed that functional analysis of the GABAreceptor gene family mutations confirms that deleterious rare variants in these genes can cause a loss of function of the GABA receptor [54] .
An early Exome study in GGE was performed with a discovery phase comprising WES in 118 GGE cases and controls with subsequent follow-up of the most promising 3,897 candidate disease variants in a sample of 878 GGE cases and 1,830 controls [55] . No statistical significance was detected, demonstrating that no major gene underlies GGE and that a high degree of genetic heterogeneity can be expected.
Recently, a larger study was published by the Epi4K and Epilepsy Phenome/Genome project that includes 640 people with familial GGE and 525 people with familial non-acquired FE (NAFE) and 3877 controls [56] . The study performed a case-control association study that aimed to test for significant enrichment of gene variation detected by WES. It included a 'collapsing analysis" that lumped together the variants detected in known epilepsy genes for a joined analysis. Remarkably, this approach detected a significant enrichment of ultra-rare variations in established epilepsy genes with both familial GGE and NAFE, supporting their importance for common epilepsy. However, this finding was not repeated in sporadic NAFE. No single gene showed genome-wide significant enrichment of rare variation, yet the known epilepsy genes clustered in the top most enriched genes, including SCN1A in both familial GGE and NAFE.
Several sequencing studies have been performed on common FE, but these are largely focused on genes in the GATOR1/mTOR pathway [57, 58] . Mutations in these genes have been discovered in Focal Cortical Dysplasia, yet several studies showed that this observation could be extended to sporadic and familial FE with or without FCD [59] . These sequencing studies suggest that rare variants with modest to medium effect sizes can underlie common epilepsy, giving promise to large-scale sequencing studies that extend the search space of GWAS.
The future: extrapolating the current state of the art in epilepsy genetics
This concise overview of three decades of gene mapping illustrates the blurring line between a monogenic and polygenic background of common epilepsy. The clear familial clustering observed in GGE and familial FE argue for a monogenic (or digenic) cause of disease, which is indeed evidenced by several studies. On the other hand, mutations in these genes do not explain a considerable fraction of sporadic cases, suggesting that a complex genetic background must exist, which is indeed evidenced by the success of GWAS. So far, only GWAS of a reasonable size have detected a few loci, despite their power to detect a few common risk factors. This suggests a high degree of genetic heterogeneity and low effect sizes. The observation that rare CNVs also associate with sporadic GGE further complicates the picture and illustrates that relatively rare genetic variants with a modest effect size are underlying epilepsy, similar to other neuropsychiatric diseases, such as schizophrenia, yet much in contrast to common autoimmune diseases [60, 61] . The first results of large scale sequencing studies further underline that relatively rare mutations may play a significant role in the heritability of common epilepsy. It is therefore likely that a wide spectrum of genetic factors is in play, ranging from very rare mutations with large effects, through relatively rare variants with medium effect sizes, and finally to common weak risk factors (Figure 1 ). Given the lack of generalisation of familial epilepsy genes to sporadic cases, and the relatively modest results of current large GWAS of epilepsy, we may conclude that we can expect that a large number of relatively rare variants with intermediate-to medium-risk for epilepsy exist. Such loci can be detected through large, sufficiently powered WES or WGS studies, and together may explain the majority of the genetic heritability of common epilepsy. 
